Dupuytrens 疾病治療市場、機會、成長動力、產業趨勢分析與預測，2024-2032 年

2023 年，全球掌腱膜攣縮症治療市場價值約為8.894 億美元，預計2024 年至2032 年複合年成長率為12.2%。性手部畸形，影響手部下方的組織層。隨著時間的推移，組織結會形成，形成一條粗繩，可以彎曲一根或多根手指。掌腱膜攣縮症的盛行率不斷上升，大大推動了市場的發展。藥物輸送技術的進步和老年人口的不斷成長進一步促進了市場的成長。近年來，掌腱膜攣縮症的治療取得了重大進展，明顯轉向更有效、侵入性更小的治療方法，支持了其普及性和市場成長。

整個掌腱膜攣縮症治療行業根據類型、治療方法、配銷通路和地區進行分類。

按類型細分，掌腱膜攣縮症治療市場包括 I 型、II 型和 III 型。預測表明，到 2032 年，II 型細分市場將達到 13 億美元。 II 型作為最常見的疾病形式引領市場，充當較溫和的 I 型和較嚴重的 III 型之間的中介。隨著 II 型手指攣縮變得更加明顯，患者更有可能尋求醫療干預，從而推動了治療需求。膠原酶注射或手術等治療方法在 II 型階段最有效，可促進收入成長。

按治療方法細分，掌腱膜攣縮症治療市場包括膠原蛋白酶注射劑、類固醇、免疫調節劑和其他治療方法。 2023年，膠原酶注射劑的市佔率為4.892億美元。膠原酶注射提供了一種微創解決方案，將酶注射到受影響的膠原索中，無需進行手術切割。這種酵素會分解導致攣縮的膠原索，改善手指伸展和手部功能。膠原蛋白酶注射可以同時治療多個手指或關節，使其成為廣泛攣縮患者的靈活選擇，從而推動市場成長。

在對醫療治療研發 (R&D) 和創新的大力關注的推動下，德國掌腱膜攣縮症治療市場預計到 2032 年將達到 2.344 億美元。德國重視研發，擁有頂尖製藥公司和知名研究機構，密切合作，推動藥物開發和治療掌腱膜攣縮症手術技術的突破。這些機構受益於完善的醫療基礎設施和尖端技術，能夠不斷探索新的治療方法，例如微創手術和生物療法。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 掌腱膜攣縮症盛行率增加
    • 藥物傳輸技術的進步
    • 老年人口不斷增加
  • 產業陷阱與挑戰
    • 研發成本高
    • 潛在的副作用和併發症
• 成長潛力分析
• 監管環境
• 技術景觀
  • 核心技術
  • 鄰近技術
• 2023 年定價分析
  • 按地區
  • 按關鍵人物
• 未來市場趨勢
• 管道分析
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按類型，2021 - 2032

• 主要趨勢
• Ⅰ型
• II型
• Ⅲ型

第 6 章：市場估計與預測：按治療方法，2021 - 2032 年

• 主要趨勢
• 膠原蛋白酶注射液
• 類固醇
• 免疫調節劑
• 其他療法

第 7 章：市場估計與預測：按配銷通路，2021 - 2032 年

• 主要趨勢
• 零售藥房
• 醫院藥房
• 網路藥房

第 8 章：市場估計與預測：按地區，2021 - 2032

• 主要趨勢
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
  • 歐洲其他地區
• 北美洲
  • 美國
  • 加拿大
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地區
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 9 章：公司簡介

• AstraZeneca PLC
• Actiza Pharmaceutical Private Limited
• Bayer AG.
• Bristol-Meyers Squibb Company
• Endo International plc
• Fresenius SE and Co. KGaA
• Fortress Biotech, Inc.
• GSK plc
• Hikma Pharmaceuticals PLC
• Johnson and Johnson
• Merck and Co., Inc.
• Nantong Jinghua Pharmaceutical Co., Ltd
• Novartis AG
• LEO Pharma A/S
• Pfizer Inc.

The Global Dupuytren's Disease Therapeutics Market was valued at approximately USD 889.4 million in 2023 and projections indicate a growth rate of 12.2% CAGR from 2024 to 2032. Dupuytren's disease, also known as Dupuytren's contracture, is a progressive hand deformity affecting a tissue layer beneath the palm's skin. Over time, tissue knots form, leading to a thick cord that can bend one or more fingers. The increasing prevalence of Dupuytren's disease significantly drives the market. Advancements in drug delivery technologies and a growing geriatric population further bolster market growth. Recent years have seen significant strides in Dupuytren's disease therapeutics, with a clear shift towards treatments that are both more effective and less invasive, supporting their popularity and market growth.

The overall dupuytrens disease therapeutics industry is classified based on the type, therapeutics, distribution channel and region.

Segmented by type, the Dupuytren's disease therapeutics market includes type I, type II, and type III. Projections indicate the type II segment will reach USD 1.3 billion by 2032. Type II leads the market as the most common form of the disease, acting as an intermediary between the milder type I and the more severe type III. As finger contracture becomes more evident in type II, patients are more likely to seek medical intervention, driving treatment demand. Treatments like collagenase injections or surgery are most effective during the type II stage, enhancing revenue growth.

Segmented by therapeutics, the Dupuytren's disease therapeutics market includes collagenase injections, steroids, immune-modulators, and other treatments. In 2023, collagenase injections made up USD 489.2 million of the market. Collagenase injections offer a minimally invasive solution, injecting the enzyme into the affected collagen cords and eliminating the need for surgical cuts. This enzyme breaks down the collagen cords causing contractures, improving finger extension and hand function. Collagenase injections can address multiple fingers or joints at once, making it a flexible choice for patients with widespread contractures, thus propelling market growth.

Germany's Dupuytren's disease therapeutics market is set to reach USD 234.4 million by 2032, driven by a strong focus on research and development (R&D) and innovations in medical treatments. Germany emphasizes R&D, hosting top-tier pharmaceutical firms and renowned research institutions that collaborate closely to drive breakthroughs in both drug development and surgical techniques for treating Dupuytren's disease. These institutions benefit from well-established healthcare infrastructure and access to cutting-edge technology, enabling the continuous exploration of new treatment methods, such as minimally invasive procedures and biologic therapies.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence for dupuytren's disease
    • 3.2.1.2 Advancements in drug delivery technologies
    • 3.2.1.3 Rising geriatric population
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High research and development cost
    • 3.2.2.2 Potential side effects and complications
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
  • 3.5.1 Core technologies
  • 3.5.2 Adjacent technologies
• 3.6 Pricing analysis, 2023
  • 3.6.1 By region
  • 3.6.2 By key player
• 3.7 Future market trends
• 3.8 Pipeline analysis
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Type I
• 5.3 Type II
• 5.4 Type III

Chapter 6 Market Estimates and Forecast, By Therapeutics, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Collagenase injection
• 6.3 Steroids
• 6.4 Immune-modulators
• 6.5 Other therapeutics

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Retail pharmacy
• 7.3 Hospital pharmacy
• 7.4 Online pharmacy

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Europe
  • 8.2.1 Germany
  • 8.2.2 UK
  • 8.2.3 France
  • 8.2.4 Spain
  • 8.2.5 Italy
  • 8.2.6 Netherlands
  • 8.2.7 Rest of Europe
• 8.3 North America
  • 8.3.1 U.S.
  • 8.3.2 Canada
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 AstraZeneca PLC
• 9.2 Actiza Pharmaceutical Private Limited
• 9.3 Bayer AG.
• 9.4 Bristol-Meyers Squibb Company
• 9.5 Endo International plc
• 9.6 Fresenius SE and Co. KGaA
• 9.7 Fortress Biotech, Inc.
• 9.8 GSK plc
• 9.9 Hikma Pharmaceuticals PLC
• 9.10 Johnson and Johnson
• 9.11 Merck and Co., Inc.
• 9.12 Nantong Jinghua Pharmaceutical Co., Ltd
• 9.13 Novartis AG
• 9.14 LEO Pharma A/S
• 9.15 Pfizer Inc.